IDEAYA Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 124
- Market Cap
- $3.3B
- Website
- http://www.ideayabio.com
- Introduction
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
IDEAYA Biosciences, Inc. (IDYA) BCG Matrix Analysis
IDEAYA Biosciences, Inc. (IDYA) is a precision medicine oncology firm with a $1.2 billion cash reserve and a strong pipeline, including darovasertib in Phase 2/3 trials. Despite a $492.5 million deficit and reliance on external financing, collaborations with GSK and Pfizer bolster its position. The company focuses on synthetic lethality and molecular diagnostics for targeted therapies, facing challenges in revenue generation and regulatory approvals.
PESTEL Analysis of IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences navigates biotech challenges through PESTLE analysis, focusing on regulatory impacts, economic conditions, societal trends, tech advancements, legal frameworks, and environmental sustainability. Key factors include FDA approvals, GSK collaborations, R&D expenses, personalized medicine, and green tech investments, shaping its strategic direction in cancer treatment.
PESTEL Analysis of IDEAYA Biosciences, Inc.
IDEAYA Biosciences navigates biotech challenges through PESTLE analysis, focusing on regulatory impacts, economic conditions, societal trends, tech advancements, legal frameworks, and environmental sustainability. Key points include FDA approval timelines, GSK collaboration, R&D expenses, precision medicine, IP rights, and green tech investments.
© Copyright 2025. All Rights Reserved by MedPath